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Abstract
Background: Antidepressants may be used to manage a number of conditions in children and young people
including depression, anxiety, and obsessive-compulsive disorder. UK guidelines for the treatment of depression
in children and young people recommend that antidepressants should only be initiated following assessment and
diagnosis by a child and adolescent psychiatrist. The aim of this study was to summarise visits to mental health
specialists and indications recorded around the time of antidepressant initiation in children and young people in
UK primary care.
Methods: The study used linked English primary care electronic health records and Hospital Episode Statistics
secondary care data. The study included 5–17-year-olds first prescribed antidepressants between January 2006
and December 2017. Records of visits to paediatric or psychiatric specialists and potential indications (from a pre-
specified list) were extracted. Events were counted if recorded less than 12 months before or 6 months after the
first antidepressant prescription. Results were stratified by first antidepressant type (all, selective serotonin reuptake
inhibitors (SSRIs), tricyclic and related antidepressants) and by age group (5–11 years, 12–17 years).
Results: In total, 33,031 5–17-year-olds were included. Of these, 12,149 (37%) had a record of visiting a paediatrician
or a psychiatric specialist in the specified time window. The majority of recorded visits (7154, 22%) were to
paediatricians. Of those prescribed SSRIs, 5463/22,130 (25%) had a record of visiting a child and adolescent
psychiatrist. Overall, 17,972 (54%) patients had a record of at least one of the pre-specified indications. Depression
was the most frequently recorded indication (12,501, 38%), followed by anxiety (4155, 13%).
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Conclusions: The results suggest many children and young people are being prescribed antidepressants without
the recommended involvement of a relevant specialist. These findings may justify both greater training for GPs in
child and adolescent mental health and greater access to specialist care and non-pharmacological treatments.
Further research is needed to explore factors that influence how and why GPs prescribe antidepressants to children
and young people and the real-world practice barriers to adherence to clinical guidelines.
Keywords: Antidepressants, SSRIs, Epidemiology, Primary health care, Child, Adolescent, Depression, Anxiety, Mental
health
Background
Antidepressant medicines are an important treatment
option for a number of conditions in children and young
people including depression [1], anxiety [2], and
obsessive-compulsive disorder (OCD) [3]. In a 2017
survey, these conditions were found to affect 2.1%
(depressive disorders), 7.2% (anxiety disorders), and 0.4%
(OCD) of 5–19-year-olds in England [4]. In contrast, in
2015, the estimated prevalence of antidepressant use by
3–17-year-olds in the UK was 5 per 1000 patients, based
on primary care data [5].
In the UK, the National Institute for Health and Care
Excellence (NICE) produces guidelines for the treatment
of many conditions. These guidelines contain evidence-
based recommendations made by expert groups and are
tailored to the UK health system. The guidelines also
discuss the rationale behind recommendations. Regard-
ing antidepressants, the NICE guideline for the treat-
ment of depression in children and young people
(NG134 [6]) states that prescribing of antidepressants to
children and young people should follow assessment and
diagnosis by a child and adolescent psychiatrist. The
guidelines state fluoxetine should be prescribed in the
first instance, and sertraline or citalopram considered if
fluoxetine is unsuccessful or not tolerated.
Access to healthcare for both children and adults via
the UK’s National Health Service (NHS) is centralised
through general practitioners (GPs), who can initiate
treatment and/or refer patients to specialists. The major-
ity of people will therefore present to their GP in the
first instance [7]. There is evidence that access to spe-
cialist Child and Adolescent Mental Health Services
(CAMHS) is often difficult and can involve long waiting
times (an average of 57 days for those both referred and
treated in 2017/2018) [7, 8]. Faced with possible delays
in accessing CAMHS, a GP might decide to initiate anti-
depressant treatment without prior specialist involve-
ment. In studies based outside the UK, the level of
specialist involvement in antidepressant prescribing
varies. In France, where guidelines allow for non-
specialist prescribing to adolescents [9], almost 75% of
antidepressants prescribed to 6- to 17-year-olds in 2016
were initiated by GPs [10]. In Norway, on the other
hand, 84.4% of antidepressant users aged 13 to 17 in
2012 had contact with specialist health care [11].
Despite their name, which was based on their first
identified indication (depression) rather than their
mechanism(s) of action [12], antidepressants are used to
treat a number of conditions besides depression. In
those aged under 18 years, antidepressants are licensed
in the UK to treat depression, OCD, and nocturnal enur-
esis [13]. There is also evidence from systematic reviews
and meta-analyses of the effectiveness of antidepressants
in child and adolescent anxiety disorders [14, 15]. In
studies of typical antidepressant prescribing to children
and young people in the UK, depression was the pre-
dominant indication, followed by anxiety and pain [5,
16]. If the majority of antidepressants are prescribed to
treat mental health conditions, then most antidepressant
prescribing in this age group should be initiated by child
and adolescent psychiatrists if NICE guidelines [6] are
followed.
In this descriptive study, we used linked primary care
and secondary care electronic health records to summar-
ise the proportion of children and young people pre-
scribed antidepressants in primary care who had also
visited a relevant specialist. The second aim was to sum-
marise the indications associated with these antidepres-
sant prescriptions.
Methods
The protocol for this study [17] contains full methodo-
logical details.
Design and setting
This study is a descriptive observational cohort study
utilising English primary care and linked secondary care
electronic health records (EHR) between January 2006
and December 2017.
Data source
The data source was QResearch (version 43), a database
of anonymised routinely collected primary care EHR
linked to secondary care inpatient and outpatient data
(Hospital Episode Statistics (HES)). At the time of the
study, the QResearch database included EHR for over 32
Jack et al. BMC Medicine           (2020) 18:93 Page 2 of 12
million patients from more than 1500 general practices
across the UK. The EHR include patient characteristics,
clinical diagnoses, symptoms, and prescription data. The
primary care data are coded using a combination of
Read Codes (version 2) and proprietary codes from
EMIS Web, the computer system used by contributing
practices.
The primary care EHR are linked to HES data on the
basis of an anonymised version of the patient’s National
Health Service (NHS) number, a unique identifier for
patients across the UK. The inpatient and outpatient
HES data contain information including episode dates,
consultant specialty, and relevant diagnoses coded using
the ICD-10 terminology.
Cohort definition and study window
The study population was a subset of a larger cohort as
described in the protocol [17]. Patients were eligible for
inclusion if they were aged 5–17 years between 1 January
2006 and 31 December 2017 and were prescribed an
antidepressant. This window follows the publication of
the National Institute for Health and Care Excellence
(NICE) guideline for depression in children and young
people in 2005 [6]. Cohort entry was the latest date of
the following: patient registration with their general
practice plus 12 months, practice installation of the
EMIS Web computer system plus 12 months, 1 January
of the year the patient turned 5 years old, or 1 January
2006. Patients were followed up until the earliest date of
the following: patient leaving the practice, patient death,
1 January of the year the patient turned 18 years old, or
31 May 2018. Patients were included if their first-ever
antidepressant prescription was recorded during the
study window. Patients were excluded if they had re-
ceived an antidepressant prescription prior to cohort
entry.
Antidepressant prescriptions
Antidepressant prescriptions were identified in the pri-
mary care EHR using a pre-specified code list. The list
was generated based on the associated chapter of the
British National Formulary [18] (see protocol [17] for
further details). Three categories were analysed: any
antidepressant, selective serotonin reuptake inhibitors
(SSRIs), and tricyclic and related antidepressants (TCAs).
The ‘any antidepressant’ category includes all antidepres-
sants, including those not categorised as an SSRI or
TCA. The first-ever antidepressant prescribed within the
study window was identified for each patient. Patients
may be included in more than one category if they re-
ceived a prescription for more than one type of anti-
depressant on the same day.
Visits to specialists and antidepressant indications
Table 1 shows the pre-specified consultant specialities
and antidepressant indications included. Information on
secondary care consultant specialties was extracted from
coded fields within the HES dataset. We extracted data
for selected relevant specialties listed in the HES Data
Dictionary [19], including ‘paediatrics’, ‘child and adoles-
cent psychiatry’, and other psychiatry specialties. As per
NICE guidelines for depression [6] and obsessive-
compulsive disorder [20], initiation of antidepressants
for mental health conditions in children and young
people should be guided by a child and adolescent
psychiatrist. It is possible some of the older members of
the study population would interact with adult mental
illness specialists, who treat those aged 18 years and
over. For non-mental health conditions in children and
young people in the UK, paediatricians provide specialist
advice in the first instance.
Recorded antidepressant indications were obtained
from the primary care data. For those under 18 years,
antidepressants are licensed in the UK to treat depres-
sion, obsessive-compulsive disorder, and nocturnal
enuresis. Although unlicensed in this age group, antide-
pressants may also be useful for treating anxiety
disorders [14] and neuropathic pain [21]. Besides these
indications, the following conditions were included as
potential indications: attention deficit hyperactivity dis-
order (listed in the British National Formulary for
Children as an unlicensed indication for imipramine
[13], although not recommended in the guidelines [22]),
phobias (a licensed indication in adults [18]), self-harm
(closely associated with depression and anxiety [23]),
and autism (evidence of increased prescribing [24] des-
pite lack of evidence for efficacy [25, 26]). Clinical code
lists (Read and EMIS codes) were used to find any re-
cords of the specified indications in the primary care
data. Code lists were reviewed by members of the re-
search team which included a practising general
Table 1 Antidepressant indications and consultant specialties
examined
Indications Consultant speciality
Anxiety Adult mental illness
Attention deficit and hyperactivity
disorder
Child and adolescent
psychiatry
Autism Forensic psychiatry
Depression Paediatric neurology
Enuresis Paediatrics
Neuropathic pain Psychotherapy
Obsessive-compulsive disorder
Phobias
Self-harm
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practitioner, mental health specialists, and epidemiolo-
gists with experience of UK EHR. The code list for de-
pression included symptom codes as well as diagnosis
codes, as there is some evidence that symptom codes are
being increasingly used to code depression [16, 27]. We
used a broad ‘enuresis’ code list to capture records of
nocturnal enuresis.
Any records of the specified hospital visits or indica-
tions in the year before or 6 months after the first anti-
depressant prescription were identified. In the case of
self-harm, the window was restricted to the year before
the first antidepressant prescription so as not to include
self-harm events occurring after a prescription. The cat-
egories were not mutually exclusive; thus, each patient
may have more than one hospital visit/indication
recorded.
Patient characteristics
Sex (male/female) and age (based on the year of birth)
were defined using the primary care EHR. Age was cate-
gorised as 5–11 or 12–17 years old at the time of the
first antidepressant prescription. This was based on the
age groups specified in the NICE guidelines [6] but ex-
cluded 18-year-olds, who may have been treated as
adults. Ethnicity was classified according to the five
broad ethnic groups used in the England and Wales
2001 Census: White, Mixed, Asian or Asian British,
Black or Black British, and Chinese or other ethnic
groups. Where a patient was missing ethnicity informa-
tion in QResearch, the most recent valid ethnicity code
in HES was used where available. Patients with no re-
corded ethnicity were included as a separate group.
Townsend score [28] (at the patient postal code level) in
quintiles was used as an indicator of socio-economic sta-
tus. Patients were classified according to one of the nine
regions in England to which their general practice
belonged.
Analysis
The baseline characteristics of those prescribed any anti-
depressant, SSRIs, and TCAs were summarised. The
number and proportion of patients who had a record of
visiting each of the secondary care specialities and the
number and proportion of patients who had a record of
the indications of interest were determined. These were
summarised for the full study window (2006–2017) and
for each individual year. The full result datasets for
secondary care visits and indications over time are
provided in Additional files 1 and 2. A minimum cell
count of 5 (10 for combined groups) was used when
presenting results in accordance with disclosure con-
trol guidance [29].
Data handling and analyses were performed using
Stata/SE v15 (StataCorp LLC, TX) and R version 3.5.2.
Patient and public involvement
The research team included a patient and public involve-
ment representative (DB) who attended project meetings
and guided the development of the protocol and inter-
pretation of the results. DB is a member of the NIHR
MindTech MedTech Involvement Team (https://www.
mindtech.org.uk/involvement), a group of individuals
with lived experience of mental health conditions. Dis-
cussion of the results with DB helped shape the final
paper, with feedback incorporated into the ‘Discussion’
section.
Ethics statement
The project has been reviewed in accordance with the
QResearch agreement with East Midlands Derby Re-
search Ethics Committee [reference 18/EM/0400].
Results
In total, 33,031 children and young people met the study
inclusion criteria. Of these, 2330 (7.1%) were aged 5–11
years and 30,701 (92.9%) were aged 12–17 years. The
first antidepressant prescribed in primary care was an
SSRI for 22,130 (67.0%) patients and a TCA for 10,489
(31.8%) patients. Of the SSRI prescriptions, 13,287 (60%)
were for fluoxetine, 4641 (21%) were for sertraline, and
3945 (18%) were for citalopram. The characteristics of
the study population are summarised in Table 2. The
majority of patients were female (22,279, 67.4%), and 22,
827 (69.1%) were classified as White (ethnicity informa-
tion was missing for 24.0% of patients).
Overall, 12,149/33,031 (36.8%) children and young
people in the cohort had a record of visiting a paediatric
or psychiatric specialist in the 12 months before or 6
months after their first primary care antidepressant pre-
scription. The figures were 8387/22,130 (37.9%) for
SSRIs and 3625/10,489 (34.6%) for TCAs. Overall and
for TCAs, the most common specialty recorded was
paediatrics (7154/33,031 (21.7%) and 3144/10,489
(30.0%) respectively) (Table 3). Child and adolescent
psychiatry was the specialty most frequently recorded in
patients whose first antidepressant was an SSRI (5463/
22,130, 24.7%). The proportion of those visiting a paedi-
atric specialist increased steadily over the study period
overall and in those prescribed SSRIs or TCAs. For those
first prescribed SSRIs, the proportion of visiting a child
and adolescent psychiatrist increased from 10.7% in
2006 to a peak of 19.3% in 2013 and then decreased to
16.9% in 2017 (Fig. 1).
By patient age, 1157/2239 (49.7%) 5–11-year-olds and
10,992/30,701 (35.8%) 12–17-year-olds had a record of
visiting a paediatric or psychiatric specialist (Table 3).
Visits to specialists according to patient age and anti-
depressant type are summarised in Fig. 2. In both age
groups, those prescribed TCAs were more likely to have
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Table 2 Characteristics of the study population at the first antidepressant prescription, according to antidepressant class
Any SSRI Any TCA Any antidepressant
N 22,130 10,489 33,031
Female, n (%) 14,960 (67.6%) 7054 (67.3%) 22,279 (67.4%)
Age at first prescription, median (IQR) 16 (15–17) 16 (13–17) 16 (15–17)
Aged 5–11, n (%) 652 (2.9%) 1659 (15.8%) 2330 (7.1%)
Aged 12–17, n (%) 21,478 (97.1%) 8830 (84.2%) 30,701 (92.9%)
Townsend quintile, n (%)
1 (least deprived) 5481 (24.8%) 2670 (25.5%) 8234 (24.9%)
2 5554 (25.1%) 2515 (24.0%) 8156 (24.7%)
3 4891 (22.1%) 2200 (21.0%) 7195 (21.8%)
4 3912 (17.7%) 1798 (17.1%) 5788 (17.5%)
5 (most deprived) 2262 (10.2%) 1288 (12.3%) 3610 (10.9%)
Unknown 30 (0.1%) 18 (0.2%) 48 (0.2%)
Ethnicity, n (%)
White 15,769 (71.3%) 6786 (64.7%) 22,827 (69.1%)
Mixed 298 (1.4%) 146 (1.4%) 451 (1.4%)
Asian or Asian British 541 (2.4%) 576 (5.5%) 1130 (3.4%)
Black or Black British 191 (0.9%) 219 (2.1%) 416 (1.3%)
Chinese or Other 177 (0.8%) 81 (0.8%) 265 (0.8%)
Unknown 5154 (23.3%) 2681 (25.6%) 7942 (24.0%)
Practice region, n (%)
East Midlands 1092 (4.9%) 623 (5.9%) 1730 (5.2%)
East of England 1615 (7.3%) 869 (8.3%) 2510 (7.6%)
London 2387 (10.8%) 1341 (12.8%) 3780 (11.4%)
North East 824 (3.7%) 382 (3.6%) 1215 (3.7%)
North West 3915 (17.7%) 1499 (14.3%) 5498 (16.6%)
South East 6275 (28.4%) 2618 (25.0%) 9010 (27.3%)
South of England 2367 (10.7%) 1418 (13.5%) 3838 (11.6%)
West Midlands 2759 (12.5%) 1076 (10.3%) 3882 (11.8%)
Yorkshire and The Humber 896 (4.1%) 663 (6.3%) 1568 (4.8%)
SSRI selective serotonin reuptake inhibitor, TCA tricyclic and related antidepressant, n number, IQR interquartile range
Table 3 Visits to hospital specialists associated with the first antidepressant prescription
Consultant specialty Ages 5–11
(n = 2330)
Ages 12–17
(n = 30,701)
SSRI
(n = 22,130)
TCA
(n = 10,489)
Any antidepressant ages
5–17 (n = 33,031)
Any paediatric or psychiatric 1157 (49.7%) 10,992 (35.8%) 8387 (37.9%) 3625 (34.6%) 12,149 (36.8%)
Adult mental illness 13 (0.6%) 900 (2.9%) 833 (3.8%) 54 (0.5%) 913 (2.8%)
Child and adolescent psychiatry 285 (12.2%) 5770 (18.8%) 5463 (24.7%) 522 (5.0%) 6055 (18.3%)
Forensic psychiatry < 10 10 (< 0.1%) < 10 < 10 10 (< 0.1%)
Paediatric neurology 124 (5.3%) 567 (1.8%) 259 (1.2%) 424 (4.0%) 691 (2.1%)
Paediatrics 1000 (42.9%) 6154 (20.0%) 3940 (17.8%) 3144 (30.0%) 7154 (21.7%)
Psychotherapy 13 (0.6%) 79 (0.3%) 53 (0.2%) 39 (0.4%) 92 (0.3%)
Includes visits made less than 1 year before or 6 months after the first antidepressant prescription. Individuals may be included in both SSRI and TCA categories
and may have visited more than one type of specialist. Counts less than 10 have been masked
SSRI selective serotonin reuptake inhibitor, TCA tricyclic and related antidepressant, n number
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visited a paediatric than a psychiatric specialist. For
SSRIs, 5232 /21,478 (24.4%) 12–17-year-olds had visited
a child and adolescent psychiatrist.
Overall, 17,972/33,031 (54.4%) children and young
people in the cohort had a record of at least one of the
indications of interest in the 12 months before or 6
months after their first primary care antidepressant pre-
scription. This increased over time from 48.9% in 2006
to 67.0% in 2017 (Fig. 3). The most frequently recorded
indications were depression (n = 12,630, 38.2%) and
anxiety (n = 4155, 12.6%) (Table 4). For SSRIs, 15,295/
22,130 (69.1%) first prescriptions were assigned an indi-
cation, and for TCAs, the proportion was 2463/10,489
(23.5%). The most frequently recorded indication for
both SSRIs (11,537/22,130, 52.1%) and TCAs (936/10,
489, 8.9%) was depression (Table 4). Considering the
other licensed indications, 774/22,130 (3.5%) SSRI
prescriptions had an indication of obsessive-compulsive
disorder recorded and 877/10,489 (8.4%) TCA prescrip-
tions had a record of enuresis. Over the study window,
the proportion of TCA prescriptions associated with
enuresis decreased from 16.0 to 5.3%. The proportion
of all first antidepressant prescriptions with records of
anxiety or depression increased between 2006 and
2017 from 6.3 to 21.9% for anxiety and 32.7 to 47.4%
for depression (Fig. 3).
For those aged 5–11 years, 998/2330 (42.8%) had a
recorded indication, and the most frequently recorded
indications were enuresis (642/2330, 27.6%) and autism
(206/2330, 8.8%) (Table 4). For those aged 12–17 years,
16,974/30,701 (55.3%) had a recorded indication, and
the most frequently recorded indications were depres-
sion (12,558/30,701, 40.9%) and anxiety (4019/30,701,
13.1%). Indications according to age and antidepressant
type are summarised in Fig. 4. Over half of the 12–17-
year-olds first prescribed SSRIs had a record of depres-
sion (11,474/21,478, 53.4%).
Discussion
This study included 33,031 children and young people in
England who were prescribed an antidepressant in pri-
mary care between January 2006 and December 2017.
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Fig. 1 Percentage of the first antidepressant prescriptions associated with visits to hospital specialists over time. Includes visits made less than 1
year before or 6 months after the first antidepressant prescription. Specialties with fewer than 5 records have been masked
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Of these, 12,149 (37%) had a record of visiting a second-
ary care paediatric or psychiatric specialist less than 12
months before or 6 months after their first primary care
antidepressant prescription. The percentage of 5–17-
year-olds prescribed antidepressants with a record of
visiting a specialist increased between 2006 and 2012,
before levelling off at approximately 39%. Considering
only those aged 12–17 years old prescribed SSRIs, 24.4%
had a record of visiting a child and adolescent psych-
iatrist. Although the proportion of visiting a child and
adolescent psychiatrist initially increased, it began to de-
crease after 2013.
These results suggest a significant proportion of
children and young people receive prescriptions for anti-
depressants without the involvement of a relevant
specialist, such as a mental health specialist or paediatri-
cian. This is contrary to the NICE guidelines for depres-
sion [6] and obsessive-compulsive disorder [20], which
recommend assessment and diagnosis by a child and
adolescent psychiatrist before the initiation of antide-
pressants, and nocturnal enuresis [30], which recom-
mends referral for further review and assessment of
possible underlying factors before initiation of imipra-
mine. There could be several reasons for this, including
the lack of awareness of relevant guidelines by GPs.
However, one small qualitative study suggested good un-
derstanding of the depression guidelines amongst GPs in
interviews [31]. Another explanation for GPs initiating
antidepressants without the involvement of a specialist
could be a lack of prompt access to secondary care ser-
vices or evidence-based non-pharmacological treatments
such as cognitive behavioural therapy. There is limited
availability of specialist services leading to long waiting
times (average 57 days in 2017/2018) [8] and strict ac-
ceptance criteria [32]. According to reports by the Chil-
dren’s Commissioner for England, provision of low-level
(non-specialist, preventative, and early intervention)
mental health services is complicated and variable across
the country [33]. If a GP feels a child or young person
needs urgent treatment for their mental health condi-
tion, and other non-pharmacological options and spe-
cialist assessment are not immediately available, they
may choose to prescribe antidepressants despite the rec-
ommendations of clinical guidelines. In addition, pa-
tients or their parents may decline other treatment
options or request antidepressants. For example, some
of the adolescents in one qualitative study described that
without SSRIs, they felt too low to benefit from alterna-
tive therapies [34].
We also explored the indications associated with anti-
depressant prescribing to children and young people.
Where indications were identified, depression was the
most frequently recorded indication overall (38%), echo-
ing the findings of other studies utilising UK EHR [5, 16,
35]. John et al. [16] found over half of new antidepres-
sants prescribed to 6–18-year-olds between 2003 and
Fig. 2 Percentage of the first antidepressant prescriptions associated with visiting a hospital specialist. Includes visits made less than 1 year before
or 6 months after the first antidepressant prescription. SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant;
n, number. Specialties with fewer than 5 records have been masked
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Table 4 Indications associated with the first antidepressant prescription
Indication Ages 5–11
(n = 2330)
Ages 12–17
(n = 30,701)
SSRI
(n = 22,130)
TCA
(n = 10,489)
Any antidepressant
ages 5–17 (n = 33,031)
Any of the pre-specified indications 998 (42.8%) 16,974 (55.3%) 15,295 (69.1%) 2463 (23.5%) 17,972 (54.4%)
Anxiety 136 (5.8%) 4019 (13.1%) 3601 (16.3%) 508 (4.8%) 4155 (12.6%)
Attention deficit hyperactivity disorder < 10 61 (0.2%) 50 (0.2%) 14 (0.1%) 66 (0.2%)
Autism 206 (8.8%) 1020 (3.3%) 1127 (5.1%) 90 (0.9%) 1226 (3.7%)
Depression 72 (3.1%) 12,558 (40.9%) 11,537 (52.1%) 936 (8.9%) 12,630 (38.2%)
Enuresis 642 (27.6%) 308 (1.0%) 73 (0.3%) 877 (8.4%) 950 (2.9%)
Neuropathic pain < 10 104 (0.3%) < 10 107 (1.0%) 113 (0.3%)
Obsessive compulsive disorder 53 (2.3%) 751 (2.4%) 774 (3.5%) 28 (0.3%) 804 (2.4%)
Phobias < 10 260 (0.8%) 222 (1%) 40 (0.4%) 268 (0.8%)
Self-harm 10 (0.4%) 2948 (9.6%) 2715 (12.3%) 190 (1.8%) 2958 (9.0%)
Includes indications recorded less than 1 year before or 6 months after the first antidepressant prescription. Individuals may be included in both SSRI and TCA
categories and may have records of more than one indication. Counts less than 10 have been masked
SSRI selective serotonin reuptake inhibitor, TCA tricyclic and related antidepressant, n number
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2013 were associated with a depressive disorder or
depression-related symptoms. Like this earlier study, we
used a broad code list to capture depression which in-
cluded symptom codes (e.g. ‘low mood’) as well as diag-
nostic codes. The figure we report is therefore likely to
be higher than the true proportion of patients with a
diagnosis of depression. Furthermore, the depression
code list included mixed anxiety and depression codes
(not included in the anxiety code list). Depression and
anxiety often co-exist, particularly in older children and
adolescents.
We were unable to identify an indication for a large
proportion of patients in the cohort (46% overall). This
was the case for around a third of patients first pre-
scribed SSRIs (31%) and much higher for those first pre-
scribed TCAs (77%). The proportion of patients with a
record of one of the indications of interest increased
over the study window, particularly for those prescribed
SSRIs. For patients prescribed SSRIs in the final year of
the study period (2017), 57% had a record of depression
and 25% had a record of anxiety. In this study, we used
a pre-specified list of indications, and it is possible that
some indications were missed. Sarginson et al. explored
antidepressant prescriptions to 3–17-year-olds between
2000 and 2015 using UK EHR [5]. They reported a num-
ber of indications in addition to those in our study, but
all were associated with a small percentage of
prescriptions: eating disorder (0.8%), headache disorder
(2.3%), and abdominal pain/irritable bowel syndrome
(2.3%) [5].
Overall, missing information about antidepressant in-
dications makes it difficult to assess whether antidepres-
sants were prescribed for evidence-based indications
(whether licensed or ‘off-label’). Despite this, it may be
reasonable to assume the majority of SSRIs were pre-
scribed to treat mental health conditions, particularly to-
wards the end of the study period. As discussed later,
several factors may influence clinical coding. The use of
codes in UK primary care is generally at the clinician’s
discretion, and the lack of a coded indication does not
necessarily imply a gap in care provision.
Strengths of this study include the use of QResearch, a
large, population-based primary care database which
captures all prescriptions issued from participating gen-
eral practices, and linkage with a secondary care data-
base which captures all NHS hospital visits made by
patients in England. The QResearch database includes
data from a sample of practices using EMIS Web soft-
ware, the most widely used and widely distributed clin-
ical computer system in England [36]. As a result, the
study cohort is likely to be a representable sample of
children and young people in England, and the study
findings are likely to be generalisable to primary care
across the country. Another strength is that our time
Fig. 4 Percentage of the first antidepressant indications associated with each recorded indication. Includes indications recorded less than 1 year
before or 6 months after the first antidepressant prescription. SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant;
n, number; OCD, obsessive-compulsive disorder; ADHD, attention deficit hyperactivity disorder. Indications with fewer than 5 records have
been masked
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window for specialist visits includes the immediate
period following as well as before primary care initiation
of prescribing. This allows for the possibility that in ur-
gent cases, prescribing may be initiated in primary care
together with a secondary care referral. Hence, we are
unlikely to have underestimated the true proportion of
antidepressant prescribing where there has been no sec-
ondary care involvement.
The following limitations should be considered when
interpreting the results of this study. First, it is possible
that we did not capture all interactions with specialists.
While the majority of specialist consultants in paediat-
rics and CAMHS are likely to be based in secondary
care, it is possible some may be based in a community
setting which would not be captured within HES. The
HES dataset does not include data about privately
funded medical care. However, in the UK, the vast ma-
jority of children and young people receive healthcare
provided by the NHS. This study will not have captured
any hospital visits that occurred more than 12months
before or 6 months after the first primary care prescrip-
tion was issued. Misclassification within the consultant
specialty field of the HES dataset could also have re-
sulted in some visits being missed. However, in this
study, the association between antidepressant prescrip-
tions and specialist visits was based entirely on their
relative timing, and many of the visits (particularly to
paediatrics) may have been for unrelated issues. On bal-
ance, therefore, we believe these figures are more likely
to be overestimates.
Second, we identified indications based on the diag-
nostic codes recorded by clinicians. Indications would
only be captured if coded in the patient’s record and if
the code lists we applied captured all relevant cases. UK
general practice records contain a mixture of coded and
free-text information, and coding can depend on factors
such as severity, whether the consultation is the first
presentation of symptoms, and whether the condition is
included in the Quality and Outcomes Framework
(QOF) which provides financial incentives for the man-
agement of certain conditions [37]. In this study, it is
possible that conditions were recorded in free-text re-
cords but never coded, and thus unavailable in the data-
sets used. Originally, we planned to supplement the
primary care data with diagnosis information from HES.
Upon examination, however, the secondary care data
identified very few additional cases (e.g. 3% increase in
the number of patients with a depression diagnosis
code), and so only the primary care data were used for
this purpose. The code lists used in this study were cre-
ated by experienced clinicians with expertise in UK pri-
mary care and psychiatry. The majority of code lists
(except depression, as discussed earlier) included diag-
nostic codes but not symptom codes. It is possible that
the frequency of indications with these narrower defini-
tions was underestimated, depending on the coding pref-
erences of clinicians. In summary, it is possible that
relevant information about antidepressant indications is
available to clinicians while providing clinical care. How-
ever, based on the information typically available at scale
to researchers, it is difficult to identify antidepressant in-
dications for a significant proportion of the population
of interest.
Third, the prescription data only represent prescrip-
tions issued within primary care. The prescriptions in-
cluded in the study may not be the patients’ first-ever
antidepressant if the first prescription was issued in sec-
ondary care. However, when the first prescription occurs
in secondary care, prescribing will normally be trans-
ferred to primary care, meaning these patients are likely
to be represented in our analysis. The full clinical picture
will be more complex than presented in this study and
conclusions about prescribing behaviour should be lim-
ited to primary care.
This paper does not provide any new evidence about
the rates of antidepressant prescribing in this population
or possible changes to the relative frequency of prescrib-
ing of different antidepressants. Several existing studies
have demonstrated increases in antidepressant prescrib-
ing in the years up to 2015 [5, 16, 35, 38, 39], and in fu-
ture work, we will explore whether these trends have
continued in more recent years (see protocol [17]).
Conclusions
A minority (37%) of children and young people pre-
scribed antidepressants in English primary care had a
record of visiting an NHS-funded paediatric or psychi-
atric specialist less than 12months before or 6months
after their first antidepressant prescription. While a
small proportion of patients may have visited specialists
outside the NHS, overall, these results suggest that many
children and young people are being prescribed antide-
pressants without the involvement of a relevant
specialist. This practice diverges from UK clinical
guidance and may represent difficulty accessing
specialists or evidence-based non-pharmacological inter-
ventions. These findings may justify both greater
training for GPs in child and adolescent mental health
and greater access to specialist care and non-
pharmacological treatments. In 46% of patients, it was
not possible to determine the likely indication for the
antidepressants; thus, it is difficult to assess whether the
antidepressants were prescribed for evidence-based indi-
cations. Further research is needed to explore the factors
that influence how and why GPs prescribe antidepres-
sants to children and young people and the real-world
practice barriers to adherence to clinical guidelines.
Jack et al. BMC Medicine           (2020) 18:93 Page 10 of 12
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01560-7.
Additional file 1. VisitsOverTime.csv, data showing percentage of
patients with a visit to each specialty by year and antidepressant type
(used for Fig. 1).
Additional file 2. IndicationsOverTime.csv, data showing percentage
patients with a record of each indication by year and antidepressant type
(used for Fig. 3).
Abbreviations
CAMHS: Child and Adolescent Mental Health Services; EHR: Electronic health
records; EMIS: Egton Medical Information Systems (a supplier of electronic
patient record systems); GP: General practitioner; HES: Hospital Episode
Statistics; NHS: National Health Service; NICE: National Institute for Health and
Care Excellence; NIHR: National Institute for Health Research; QOF: Quality
and Outcomes Framework; SSRI: Selective serotonin reuptake inhibitor;
TCA: Tricyclic and related antidepressant; UK: United Kingdom
Acknowledgements
The authors thank the patients and EMIS practices who contribute to the
QResearch database, EMIS and the University of Nottingham for the
expertise in establishing and developing the QResearch database, and the
University of Oxford for its continued support and development. The
Hospital Episode Statistics data used in this analysis are re-used with permis-
sion from NHS Digital who retains the copyright in that data. NHS Digital
bears no responsibility for the analysis or interpretation of the data.
Authors’ contributions
Conception and design: JHC, CC, RHJ, CH, RM, RDK
Data analysis: RHJ
Interpretation: all authors
Drafting of the manuscript: RMJ, RHJ, CC, and JHC
Critical revision of the manuscript: all authors
Approval of the final version: all authors
Agreement of accountability: all authors
Funding
This work has been funded by the National Institute for Health Research
(NIHR). The research reported in this paper was conducted by the NIHR
Nottingham Biomedical Research Centre. RM is supported by the NIHR
MindTech MedTech and in Vitro Fertilisation Collaboration and the NIHR
Applied Research Collaboration East Midlands. AC is supported by the NIHR
Oxford Cognitive Health Clinical Research Facility, by an NIHR Research
Professorship (grant RP-2017-08-ST2-006) and by the NIHR Oxford Health Bio-
medical Research Centre (grant BRC-1215-20005). The views represented are
the views of the authors alone and do not necessarily represent the views of
the Department of Health in England, NHS, or the National Institute for
Health Research.
The funder had no role in the design, analysis, and interpretation of the data
or in writing the manuscript.
Availability of data and materials
The datasets analysed during the current study are not publicly available as
they are provided under agreement with QResearch (https://www.qresearch.
org/). The patient-level data from the QResearch database are specifically
licensed according to its governance framework, see http://www.qresearch.
org for details. The full statistical code is available from the authors.
Ethics approval and consent to participate
The study used anonymised data provided by QResearch and NHS Digital.
The project has been reviewed in accordance with the QResearch
agreement with East Midlands Derby Research Ethics Committee [reference
18/EM/0400].
Consent for publication
Not applicable
Competing interests
CH was the chair of the NICE guideline for psychosis in children and young
people (CG155) and a member of the NICE ADHD Guideline update
committee (NG87).
SC has received honoraria for talks/lectures from the Association for Child
and Adolescent Mental Health (ACAMH), British Association of
Psychopharmacology (BAP), Canadian ADHD Alliance Resource (CADDRA),
and Healthcare Convention.
JHC is a professor of clinical epidemiology and general practice at the
University of Oxford and co-director of QResearch®—a not-for-profit organ-
isation which is a joint partnership between the University of Oxford and
Egton Medical Information Systems (the leading commercial supplier of IT
for 60% of general practices in the UK). JHC was also a paid director of Clin-
Risk Ltd. which produces open and closed source software to ensure the reli-
able and updatable implementation of clinical risk equations within clinical
computer systems to help improve patient care.
RHJ, RMJ, CC, DB, RM, RDK, and AC declare that they have no competing
interests.
Author details
1Division of Primary Care, School of Medicine, University of Nottingham,
Nottingham, UK. 2National Institute of Health Research MindTech MedTech
Co-operative, The Institute of Mental Health, University of Nottingham,
Nottingham, UK. 3National Institute of Health Research Nottingham
Biomedical Research Centre, Nottingham University Hospitals NHS Trust,
Nottingham, UK. 4Division of Psychiatry and Applied Psychology, School of
Medicine, University of Nottingham, Nottingham, UK. 5School of Pharmacy,
University of Nottingham, Nottingham, UK. 6Department of Psychiatry,
University of Oxford, Oxford, UK. 7Oxford Health NHS Foundation Trust,
Warneford Hospital, Oxford, UK. 8Center for Innovation in Mental Health,
School of Psychology, Faculty of Environmental and Life Sciences, Clinical
and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine,
University of Southampton, Southampton, UK. 9Solent NHS Trust,
Southampton, UK. 10Department of Child and Adolescent Psychiatry,
Hassenfeld Children’s Hospital at NYU Langone, New York, NY, USA.
11Nuffield Department of Primary Care Health Sciences, University of Oxford,
Oxford, UK.
Received: 26 November 2019 Accepted: 16 March 2020
References
1. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
antidepressants for depressive disorders in children and adolescents.
Cochrane Database Syst Rev. 2012;11:CD004851. https://doi.org/10.1002/
14651858.CD004851.pub3.
2. Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and
tolerability of antidepressants in pediatric anxiety disorders: a systematic
review and meta-analysis. Depress Anxiety. 2015;32(3):149–57. https://doi.
org/10.1002/da.22329.
3. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety
disorders in children and adolescents. Cochrane Database Syst Rev. 2009;3:
CD005170. https://doi.org/10.1002/14651858.CD005170.pub2.
4. NHS Digital. Mental health of children and young people in England, 2017:
Emotional Disorders 2018. https://digital.nhs.uk/data-and-information/
publications/statistical/mental-health-of-children-and-young-people-in-
england/2017/2017#key-facts. Accessed 13 Mar 2020.
5. Sarginson J, Webb RT, Stocks SJ, Esmail A, Garg S, Ashcroft DM.
Temporal trends in antidepressant prescribing to children in UK primary
care, 2000-2015. J Affect Disord. 2017;210:312–8. https://doi.org/10.1016/
j.jad.2016.12.047.
6. National Institute for Health and Care Excellence. Depression in children
and young people: identification and management (clinical guideline
NG134). 2019. https://www.nice.org.uk/guidance/ng134. Accessed 08
Nov 2019.
7. Rainer C, Crellin R. Finding help: children, young people and families
navigating the system to get the mental health support they need. London:
The Children’s Society; 2019.
8. Children’s Commissioner. Children’s mental health briefing. London:
Children’s Commissioner for England; 2018.
Jack et al. BMC Medicine           (2020) 18:93 Page 11 of 12
9. Mise au point - Le bon usage des antidépresseurs chez l’enfant et l’adolescent.
Agence Française de Sécurité Sanitaire des Produits de Santé; 2008.
10. Revet A, Montastruc F, Raynaud JP, Baricault B, Montastruc JL, Lapeyre-
Mestre M. Trends and patterns of antidepressant use in French children and
adolescents from 2009 to 2016: a population-based study in the French
health insurance database. J Clin Psychopharmacol. 2018;38(4):327–35.
https://doi.org/10.1097/JCP.0000000000000891.
11. Hartz I, Skurtveit S, Hjellvik V, Furu K, Nesvag R, Handal M. Antidepressant
drug use among adolescents during 2004-2013: a population-based register
linkage study. Acta Psychiatr Scand. 2016;134(5):420–9. https://doi.org/10.
1111/acps.12633.
12. Sultan RS, Correll CU, Zohar J, Zalsman G, Veenstra-VanderWeele J. What’s in
a name? Moving to neuroscience-based nomenclature in pediatric
psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2018;57(10):719–
21. https://doi.org/10.1016/j.jaac.2018.05.024.
13. Paediatric Formulary Committee. BNF for Children (online). http://www.
medicinescomplete.com. Accessed 08 Nov 2019.
14. National Institute for Health and Care Excellence. Generalised anxiety disorder
and panic disorder in adults: management (clinical guideline CG113). 2011.
https://www.nice.org.uk/guidance/cg113. Accessed 08 Nov 2019.
15. Patel DR, Feucht C, Brown K, Ramsay J. Pharmacological treatment of
anxiety disorders in children and adolescents: a review for practitioners.
Transl Pediatr. 2018;7(1):23–35. https://doi.org/10.21037/tp.2017.08.05.
16. John A, Marchant AL, Fone DL, McGregor JI, Dennis MS, Tan JO, et al.
Recent trends in primary-care antidepressant prescribing to children and
young people: an e-cohort study. Psychol Med. 2016;46(16):3315–27. https://
doi.org/10.1017/S0033291716002099.
17. Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Cipriani A, et al. Trends
in antidepressant prescriptions in children and young people in England,
1998-2017: protocol of a cohort study using linked primary care and
secondary care datasets. Evid Based Ment Health. 2019;22(3):129–33. https://
doi.org/10.1136/ebmental-2019-300097.
18. Joint Formulary Committee. British National Formulary (online). http://www.
medicinescomplete.com. Accessed 08 Nov 2019.
19. NHS Digital. NHS Data Model and Dictionary version 3: MAIN SPECIALTY
CODE. 2019. https://www.datadictionary.nhs.uk/data_dictionary/attributes/
m/main_specialty_code_de.asp. Accessed 08 Nov 2019.
20. National Institute for Health and Care Excellence. Obsessive-compulsive
disorder and body dysmorphic disorder: treatment (clinical guideline CG31).
2005. https://www.nice.org.uk/guidance/cg31. Accessed 08 Nov 2019.
21. National Institute for Health and Care Excellence. Neuropathic pain in adults:
pharmacological management in non-specialist settings (clinical guideline
CG173). 2019. https://www.nice.org.uk/guidance/CG173. Accessed 08 Nov 2019.
22. National Institute for Health and Care Excellence. Attention deficit
hyperactivity disorder: diagnosis and management (clinical guideline NG87).
2018. https://www.nice.org.uk/guidance/ng87. Accessed 08 Nov 2019.
23. National Institute for Health and Care Excellence. Self-harm in over 8s: long-
term management (clinical guideline 133). 2011. https://www.nice.org.uk/
guidance/CG133. Accessed 08 Nov 2019.
24. Birch RC, Foley KR, Pollack A, Britt H, Lennox N, Trollor JN. Problems
managed and medications prescribed during encounters with people with
autism spectrum disorder in Australian general practice. Autism. 2018;22(8):
995–1004. https://doi.org/10.1177/1362361317714588.
25. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin
reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane
Database Syst Rev. 2013;8:CD004677. https://doi.org/10.1002/14651858.
CD004677.pub3.
26. Hurwitz R, Blackmore R, Hazell P, Williams K, Woolfenden S. Tricyclic
antidepressants for autism spectrum disorders (ASD) in children and
adolescents. Cochrane Database Syst Rev. 2012;3:CD008372. https://doi.org/
10.1002/14651858.CD008372.pub2.
27. Mitchell C, Dwyer R, Hagan T, Mathers N. Impact of the QOF and the NICE
guideline in the diagnosis and management of depression: a qualitative
study. Br J Gen Pract. 2011;61(586):e279–89. https://doi.org/10.3399/
bjgp11X572472.
28. Townsend P. Deprivation. J Soc Policy. 2009;16(2):125–46. https://doi.org/10.
1017/s0047279400020341.
29. Office for National Statistics. Review of the dissemination of health statistics:
confidentiality guidance. 2006. https://www.ons.gov.uk/methodology/
methodologytopicsandstatisticalconcepts/disclosurecontrol/healthstatistics.
Accessed 08 Nov 2019.
30. National Institute for Health and Care Excellence. Bedwetting in under 19s
(clinical guideline CG111). 2010. https://www.nice.org.uk/guidance/cg111.
Accessed 08 Nov 2019.
31. Hinrichs S, Owens M, Dunn V, Goodyer I. General practitioner experience
and perception of Child and Adolescent Mental Health Services (CAMHS)
care pathways: a multimethod research study. BMJ Open. 2012;2(6). https://
doi.org/10.1136/bmjopen-2012-001573.
32. Crenna-Jennings W, Hutchinson J. Access to children and young people’s
mental health services - 2018. London: Education Policy Institute; 2018.
33. Children’s Commissioner. Early access to mental health support. London:
Children’s Commissioner for England; 2019.
34. Maroun RA, Thackeray LA, Midgley N. Meaning and medication: a thematic
analysis of depressed adolescents’ views and experiences of SSRI
antidepressants alongside psychological therapies. BMC Psychiatry. 2018;
18(1):374. https://doi.org/10.1186/s12888-018-1961-y.
35. Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
prescribing in children and adolescents: a cohort study in The Health
Improvement Network (THIN). PLoS One. 2012;7(3):e33181. https://doi.org/
10.1371/journal.pone.0033181.
36. Kontopantelis E, Stevens RJ, Helms PJ, Edwards D, Doran T, Ashcroft DM.
Spatial distribution of clinical computer systems in primary care in England
in 2016 and implications for primary care electronic medical record
databases: a cross-sectional population study. BMJ Open. 2018;8(2):e020738.
https://doi.org/10.1136/bmjopen-2017-020738.
37. Kendrick T, Stuart B, Newell C, Geraghty AW, Moore M. Changes in rates of
recorded depression in English primary care 2003-2013: time trend analyses
of effects of the economic recession, and the GP contract quality outcomes
framework (QOF). J Affect Disord. 2015;180:68–78. https://doi.org/10.1016/j.
jad.2015.03.040.
38. Tiffin PA, Mediavilla JL, Close H, Kasim AS, Welsh P, Paton LW, et al. What
were the impacts of the Committee on Safety of Medicines warning and
publication of the NICE guidelines on trends in child and adolescent
antidepressant prescribing in primary care? A population based study. BMJ
Open. 2019;9(8):e028201. https://doi.org/10.1136/bmjopen-2018-028201.
39. Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al.
Influences on antidepressant prescribing trends in the UK: 1995-2011. Soc
Psychiatry Psychiatr Epidemiol. 2017;52(2):193–200. https://doi.org/10.1007/
s00127-016-1306-4.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Jack et al. BMC Medicine           (2020) 18:93 Page 12 of 12
